Drug intelligence / Profile preview

Dianeal PD4

Development stage
Unknown
Lead developer
Takeda
Modality
Small Molecules
Administration
Intraperitoneal
01

Overview

Dianeal PD4 is a peritoneal dialysis solution used for the treatment of kidney failure. It is a glucose-based solution containing electrolytes including sodium chloride, calcium chloride, magnesium chloride, and sodium lactate as a bicarbonate precursor. The solution works through osmosis and diffusion across the peritoneal membrane to remove water and waste products from the blood while correcting abnormal levels of blood components. Dianeal PD4 is available in multiple glucose concentrations (1.36%, 2.27%, and 3.86%), with higher glucose concentrations providing greater fluid removal capacity. The solution is administered intraperitoneally through a catheter into the peritoneal cavity. Dianeal PD4 is particularly useful for controlling serum calcium and phosphate levels in renal failure patients receiving calcium or magnesium-containing phosphate binders. The solution has a low calcium formulation (1.25 mmol/L) compared to standard peritoneal dialysis solutions. Manufactured by Baxter Healthcare, Dianeal PD4 has been used globally for over 40 years and is currently sold in over 75 countries worldwide.

Brand names
Dianeal PD4
Other names
Dianeal PD-4

Beyond the preview

Go deeper on Dianeal PD4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dianeal PD4.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call